Barclays’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.07M Hold
60,000
﹤0.01% 1623
2025
Q4
$9.83M Buy
+60,000
New +$9.4M ﹤0.01% 1688
2025
Q3
Sell
-20,000
Closed -$2.49M 5693
2025
Q2
$2.49M Buy
+20,000
New +$2.55M ﹤0.01% 2688
2024
Q3
Sell
-121,000
Closed -$15.3M 5438
2024
Q2
$15.3M Sell
121,000
-257,100
-68% -$40.3M ﹤0.01% 1030
2024
Q1
$69.5M Buy
+378,100
New +$72M 0.02% 489
2015
Q2
Sell
-90,000
Closed -$2.7M 7170
2015
Q1
$2.7M Sell
90,000
-185,000
-67% -$4.8M ﹤0.01% 2040
2014
Q4
$5.22M Buy
+275,000
New +$6.15M 0.01% 1670

Other funds holding RGEN

Barclays's RGEN Position: Q1 2026 in Review

Barclays increased its Repligen (RGEN) stake by 22% in Q1 2026, buying an estimated $4.87M and bringing the position to 194,016 shares worth $22.9M. The position accounts for 0.01% of the portfolio, ranked #1038.

Barclays first reported a position in RGEN in Q2 2013 and has held it in 52 quarters since. The position peaked at $34.3M in Q3 2025. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

  • Barclays held 194,016 shares of Repligen worth $22.9M as of Q1 2026.
  • Barclays bought 34,864 Repligen shares in Q1 2026, an estimated $4.87M.
  • Repligen made up 0.01% of Barclays's portfolio in Q1 2026, its #1038 holding.
  • Barclays first reported a position in Repligen in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Repligen position peaked at $34.3M in Q3 2025.
  • 441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.